The health and economic repercussions of declining MMR coverage in the United States

This study quantifies the substantial and growing economic burden of measles in the United States, demonstrating that even marginal annual declines in MMR vaccination coverage can trigger a nonlinear surge in cases, hospitalizations, and costs, potentially reaching $7.77 billion over five years.

The Gist

Imagine the United States as a massive, bustling city where everyone is trying to stay healthy. For decades, this city has been protected by a giant, invisible "force field" called herd immunity. This force field is made up of millions of people who have been vaccinated against measles. As long as enough people have the shield, the virus can't get in, and the city stays safe.

However, this new study warns that the force field is developing cracks. Because fewer parents are vaccinating their young children, the shield is getting weaker. The researchers used a sophisticated "crystal ball" (mathematical models) to predict what happens if this trend continues.

Here is the breakdown of their findings in simple terms:

1. The Current Situation: A Leaking Roof

In 2025, the "roof" of the city started leaking. Measles, a disease we thought was mostly gone, came back.

• The Cost: The study found that every single case of measles in 2025 cost the country about $105,000.
• Where the money went: Surprisingly, most of this money wasn't spent on doctors' bills or hospital stays (which only made up about 3%). Instead, the biggest chunk of cash (65%) went to fighting the fire. This includes public health workers tracking down everyone the sick person met, testing them, and giving emergency vaccines to stop the spread. The rest was lost because parents and workers had to stay home (productivity loss).
• The Geography: The cost wasn't the same everywhere. In neighborhoods where the "force field" was already weak (low vaccination rates), the cost per case was much higher. It's like trying to put out a fire in a house full of dry wood; it costs more and spreads faster.

2. The Warning: A Small Crack Becomes a Canyon

The researchers asked a scary question: What happens if we just stop vaccinating a tiny bit more every year?

They imagined a scenario where vaccination rates among young children drop by just 1% each year. That sounds small, like a slow leak in a tire. But because measles is so contagious, this small leak turns into a disaster very quickly.

• The Domino Effect: By 2030, that tiny 1% drop leads to a seven-fold explosion in cases.
  • Instead of a few thousand cases, we could see 17,000+.
  • Instead of a few hundred hospitalizations, we could see 4,000+.
  • Tragically, this could lead to 36 deaths.
• The Price Tag: The economic bill for this scenario would skyrocket to $1.5 billion in a single year, and over five years, it would cost the country nearly $8 billion.

3. The "Imported Spark" Analogy

Measles doesn't just appear out of nowhere; it often enters the country from travelers coming from other parts of the world (importation).

• The Analogy: Think of the virus as a spark and the unvaccinated population as dry grass.
  • If the grass is wet (high vaccination), a spark might land, sizzle, and die out.
  • If the grass is dry (low vaccination), that same spark can ignite a massive forest fire.
• The study shows that as vaccination rates drop, even a few travelers bringing the virus in can trigger massive outbreaks that wouldn't have happened before.

4. Why This Matters (The "Hidden" Costs)

The study points out that the $105,000 cost per case is actually a lowball estimate. It doesn't fully count:

• The "Lost Potential": When kids miss school, they might learn less, which can lower their future earnings.
• The "Long-Term Ghost": Some people get a rare, deadly complication years later called SSPE (a brain disease). The cost of treating this is huge, but it's hard to predict.
• The Value of Life: The study didn't even try to put a dollar value on the lives lost, because that's a difficult calculation. If they did, the costs would be even higher.

The Bottom Line

This paper is a warning siren. It tells us that vaccination isn't just a personal choice; it's a community shield.

If we let that shield erode, even by a tiny amount, we aren't just risking a few sick kids. We are inviting a financial and health disaster that will cost billions of dollars, fill hospitals, and take lives. The study concludes that keeping vaccination rates high is the cheapest, safest, and smartest way to protect the country's future.

In short: A little bit of protection goes a long way. A little bit less protection costs a fortune.

Technical Summary

1. Problem Statement

The United States is facing a resurgence of measles due to declining childhood Measles-Mumps-Rubella (MMR) vaccination coverage, exacerbated by policy shifts (e.g., changes to vaccine schedules, Medicaid cuts) and reduced healthcare access. While measles was previously eliminated in the US, recent outbreaks in 2025 threaten this status. There is a critical lack of systematic, national-level quantification regarding the economic burden of these outbreaks and the projected consequences of continued coverage declines. Specifically, the study addresses:

• The current economic cost of measles in 2025.
• The heterogeneity of costs across counties based on local immunity levels.
• The nonlinear impact of marginal annual declines in vaccination coverage on future health outcomes and economic costs.

2. Methodology

The authors developed an integrated modeling framework combining epidemiological transmission dynamics with economic cost analysis at the county level.

• Data Inputs & Coverage Estimation:

  • Vaccination Coverage: County-level MMR coverage for children (0–6 years) was inferred using a logistic regression framework stratified by insurance type (private, public, uninsured). The model utilized kindergarten data (2017–2024), socio-demographic covariates (income, education, exemption policies), and state-level adjustments.
  • Immunity Profiles: Age-structured immunity profiles were constructed assuming a two-dose schedule (93% efficacy for dose 1, 97% for dose 2) and incorporating natural immunity for older cohorts.

• Transmission Modeling:

  • Importation: International importation events were modeled based on 2025 patterns, seeded randomly across counties proportional to population size.
  • Spatial Spread: A gravity framework simulated inter-county transmission based on population size and geographic distance.
  • Within-County Dynamics: A combination of an age-structured final-size framework and a hurdle model was used. If the effective reproduction number ($R_{E,c}$) > 1, outbreak sizes were estimated via final-size equations; if $R_{E,c} \leq 1$, a stuttering-chain branching process capped at 100 cases was used.

• Economic Costing:

  • Costs were categorized into three components: (i) Public health response (contact tracing, testing, post-exposure vaccination), (ii) Direct medical costs (outpatient/hospitalization), and (iii) Productivity losses (missed work/school).
  • Costs were expressed in 2025 USD and stratified by payer type.
  • Uncertainty Quantification: All results are derived from 2,500 Monte-Carlo simulations, reported as the mode and 50% High-Density Interval (HDI).

• Scenario Analysis:

  • Projections from 2026 to 2030 simulated annual absolute declines in coverage for children aged 0–6 years (0.25%, 0.5%, 0.75%, and 1% per year).
  • Sensitivity analyses were conducted on importation volumes (25 to 200 events/year).

3. Key Contributions

• Granular Economic Assessment: This is one of the first studies to quantify the county-level heterogeneity of measles costs, demonstrating that cost per case is inversely correlated with local population immunity.
• Comprehensive Cost Perspective: Unlike prior studies focusing primarily on medical expenditures, this model explicitly incorporates productivity losses (school/work absenteeism) and outbreak response costs, providing a broader societal view.
• Nonlinear Risk Projection: The study quantifies the "tipping point" effect, showing how small, linear declines in vaccination coverage lead to disproportionately large, nonlinear surges in cases, hospitalizations, and costs.
• Importation-Immunity Interaction: It elucidates how declining domestic immunity amplifies the impact of global importation events, creating a feedback loop that threatens elimination status.

4. Key Results

A. 2025 Baseline Burden:

• Cases: Estimated 2,181 cases (50% HDI: 719–8,176).
• Hospitalizations: 554 (50% HDI: 196–1,927).
• Deaths: 5 (50% HDI: 2–17).
• Total Economic Burden: $244.2 million (50% HDI: $69.9–$872.5 million).
• Cost per Case: $104,629 (50% HDI: $100,729–$110,140).
• Cost Composition:
  • Outbreak Response: 65.2% ($144.3M).
  • Productivity Losses: 32.1% ($84.4M).
  • Direct Medical Costs: 2.9% ($5.9M).
• Correlation: Cost per case was strongly inversely correlated with local immunity (Spearman correlation = -0.75, p < 0.001).

B. Projected Impacts of Declining Coverage (Scenario: 1% annual decline in 0–6 age group):

• 2030 Projections:
  • Cases: 17,232 (7-fold increase from 2025).
  • Hospitalizations: 4,085.
  • Deaths: 36.
  • Annual Cost: $1.50 billion (6-fold increase).
• 5-Year Cumulative Cost (2026–2030): $7.77 billion (50% HDI: $5.56–$11.58 billion).
• Sensitivity: Even a modest 0.5% annual decline results in 1,432 hospitalizations and 12 deaths by 2030.

C. Importation Dynamics:

• There is a monotonic increase in national incidence with importation events.
• The interaction between high importation pressure and low coverage is synergistic: 200 importations with a 1% coverage drop resulted in 417 additional cases compared to baseline, whereas the same drop with only 25 importations resulted in just 1 additional case.

5. Significance and Implications

• Policy Warning: The findings demonstrate that marginal reductions in MMR uptake (e.g., 0.25%–1% annually) are not linear risks but trigger exponential growth in outbreaks and economic devastation.
• Economic Efficiency: The study highlights that the majority of the economic burden stems from outbreak response and productivity losses, not direct medical care. This suggests that maintaining high vaccination coverage is the most cost-effective strategy to prevent these societal costs.
• Vulnerability of Elimination Status: The US is highly vulnerable to losing measles elimination status due to the combination of rising global importation pressure and eroding domestic herd immunity.
• Limitations & Future Work: The authors note that estimates are conservative, as they exclude long-term sequelae costs (e.g., Subacute Sclerosing Panencephalitis - SSPE) and the Value of Statistical Life (VSL). Including these would significantly increase the calculated burden.

Conclusion: The paper provides robust evidence that the resurgence of measles is driven by a convergence of policy-driven coverage declines and global importation risks. It argues that sustained investment in vaccination infrastructure is critical to prevent a projected $7.77 billion economic burden over just five years under a moderate decline scenario.